Radiofrequency treatment with Lonsurf and Avastin for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests if adding a special radiofrequency treatment to the drugs Lonsurf (TAS-102) and Avastin (bevacizumab) can help people whose colorectal cancer has spread to the liver and has not responded to previous treatments. It is for patients with limited options who have already tried at least two standard chemotherapy regimens.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to your liver.
- You have already tried at least two standard chemotherapy treatments and they no longer work or you cannot take them.
- You are 18 years or older and able to take pills by mouth.
- You are in reasonably good health (able to do daily activities without major assistance).
- Your blood counts and kidney/liver function are at safe levels as determined by blood tests.
- You have no other serious health conditions like active infections, heart problems, or other cancers that are not well-controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a new drug (retlirafusp alfa) combined with two chemotherapy drugs and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that has spread to the liver and has a specific gene change (RAS mutation). It aims to see if this combination can shrink tumors and improve outcomes in people who have not had prior treatment.
This study tests a combination of precisely targeted radiation (SBRT) with two drugs: fruquintinib (a pill that blocks blood supply to tumors) and antibodies that boost your immune system to fight cancer (PD-1 and CTLA-4 inhibitors). It is for people with advanced colorectal cancer who have already tried two standard chemotherapy treatments.
Hear when a new Refractory Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.